AI-generated analysis. Always verify with the original filing.
Pulse Biosciences, Inc. announced that Kevin P. Danahy, its Chief Commercial Officer, resigned effective immediately on February 27, 2026. The resignation was not due to any disagreement with the Company on operations, policies, practices, or accounting matters.
Event Type
Disclosure
Mandatory
Variant
8-K
DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS. On February 2
Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNA
Kevin P. Danahy
Effective: 2026-02-27
not a result of any disagreement with the Company on any matter relating to its operations, policies, or practices, or to any issues regarding its accounting policies or practices